Reports + MCP · for Launch medical leads and medical strategy
Hear the practical barriers clinicians raise before and after an approval.
Approval is not adoption. Clinicians say in public what stands between the two.
When you need it
- An upcoming approval or label expansion
- The first months after launch
- A reimbursement or guideline decision
Ask your agent
“Ahead of approval, what practical barriers do clinicians raise about using this regimen, separate from their view of the efficacy data?”
More to ask
- “Which testing or referral steps do clinicians say would have to change for this regimen to be used?”
- “What toxicity-management questions should our medical information team prepare for?”
- “Since approval, have access or cost concerns grown or faded? Show the dated sources.”
Before and after
How the work changes
Today
- Learn about implementation barriers from field reports months after launch
- Mix efficacy enthusiasm and access concerns in one sentiment score
- Miss the testing and referral bottlenecks clinicians describe in detail
With Erudio
- Barriers separated from views of the efficacy data
- Every concern linked to who raised it and when
- A signal you can follow over time, not a one-off survey
What you get
- The practical barriers clinicians name: testing, access, toxicity, monitoring
- Which concerns are about the evidence and which are about delivery
- Questions field medical will hear in the first months
Tools it calls
mcp
search_reports({ "drug": "<drug>" })
read_report({ "report_id": "<id>", "sections": ["findings"] })
search({ "query": "<drug> access reimbursement toxicity", "published_after": "<date>" })In a published report
NEONIPIGA
NCT04006262
In NEONIPIGA, clinicians tie organ preservation to surveillance infrastructure, access and toxicity management, not only to response.
- F3Dual blockade's response appeal is limited by immune toxicity, while monotherapy remains a disputed alternative
Context for these views, not raised in the commentary cited above. The trial publication reports: Neoadjuvant therapy-related grade 3/4 adverse events occurred in six patients (19%). The rate of surgical morbidity (Clavien-Dindo classification) was 55% (one postoperative death occurred).
- F8Funding and approval boundaries alter treatment delivered, even when clinicians favor immunotherapy
- F12Organ preservation requires a surveillance-and-salvage system; ctDNA and patient support do not remove its limits
What it does not do
- Implementation concerns are reported as clinicians state them, not as market research.
- No promotional messaging or claims about your product.
- Patient voices are never presented as HCP views.